

THIS MONTH'S TOPIC

First quarter 2021 results: a far better-than-expected rebound that augurs well for the full year

Debora DELBO',
Senior EM Macro Strategist



Éric MIJOT,
Head of Developed Markets
Strategy Research



Ibra WANE,
Senior Equity Research Strategist

Corporate results rebounded in Q1 2021 to a surprising extent everywhere and are likely to continue doing so beyond 2021. This could mean a new, earnings-driven phase in the equity market rally. In the shorter term, however, the markets could be tentative in the wake of their strong gains, but probably without casting any doubt on their favourable outlook nine to 12 months out, particularly regarding value stocks.

Corporate results rebounded to a surprising extent everywhere in Q1 and are likely to continue doing so beyond 2021. In the medium term, a new phase in the equity markets rally is looming – less strong but based more on fundamentals, in which earnings growth would play a more decisive role. In the shorter term, however, many flags of a recovery are nearing their peaks, and the markets could become more tentative in the wake of their strong gains, but probably without casting any doubt on their favourable outlook nine to 12 months out. Amidst a likely generalised reopening, it is probably worth sticking to a rather pro-cyclical bias, particularly with regards to value stocks. Likewise, stock-picking will become increasingly decisive. In short, alpha is likely to take over from beta.

S&P 500: An impressive Q1 on both top and bottom lines!


As of 14 May, 91% of S&P 500 companies had reported. Reporting companies beat forecasts by far. In revenue terms, first of all, after declining by 1% last year, they soared by +13% in Q1 2021, far ahead of the +9% forecast as of 1 April, i.e., at the start of reporting season. Likewise, earnings skyrocketed by +51% in Q1, much higher than the +16% the consensus was forecasting in early January and the +24% it was looking at on 1 April. This is all the

more impressive as Q1 2020 results (-13%) had not yet borne the full brunt of the Covid-19 impact. So Q1 results are not only better than last year's but 31% higher than the pre-Covid results of Q1 2019. Given that the US economy has just returned to its pre-Covid levels, the strength of the S&P's Q1 2021 rebound in revenues (+13%) and earnings (+51%) is therefore simply astounding.

That being said, trends varied widely from one sector to another. Financials and consumer discretionaries, for example, not only stood out, soaring, respectively, by +138% and +191%, they also fared better than had been expected in early April (+69% and +99%, respectively). Conversely, and unsurprisingly, utilities (-1%), real estate (+6%) and consumer staples (+7%) brought up the rear. More surprisingly, healthcare, a defensive sector, again rose very strongly in Q1 2021 (+27%), on top of its strong performance last year (+7%). Industry, however, disappointed. Cyclical, whose results had dropped in Q1 2020 (-33%) had not yet managed to take off again in Q1 2021 (+1%).

Lastly, the famous GAFAMs once again put on a display. Taken together, results of Google (+166%), Apple (+119%), Facebook (+93%), Amazon (+215%) and Microsoft (+39%) more than doubled (+104%), whereas the consensus was forecasting less than half that just before results were

1/ S&P 500 quarterly results (YoY, %)



Source: Refinitiv IBES data, Amundi Research, Data as of 14 May 2021

THIS MONTH'S TOPIC


As a result of this excellent Q1, the full-year S&P 500 EPS consensus was raised from +26 to +35%

released (+48%). Even so, the market was less than impressed. While Google and Facebook performed well, GAFAMs had underperformed on average by 1% two weeks after their reporting dates. Indeed, between the generalisation of the economic recovery and the upward pressure on interest rates, enthusiasm for growth and quality stocks has receded and could shift over to cyclicals, value stocks and financials.

As a result of this excellent first quarter, the full-year S&P 500 consensus was raised from +26% to +35%. Because of base effects and the respective weights of the various quarters, this assumes increases of +61% in Q2, +24% in Q3 and +16% in Q4. Given the strength of the US recovery and the upcoming stimulus packages, these forecasts are likely not only to be reached but probably exceeded, barring any change in tax rates¹.

¹ The Biden administration plans to raise the corporate tax rate from 21% to 28%, vs. 35% prior to the Trump reform, and to impose a minimum rate of 15%. The consensus expects this to lower the S&P 500's aggregate EPS by about 5-7%. However, there is still some uncertainty over the exact tenor of these reforms, and their effective date could be postponed to 2022 or even later.

2/ S&P 500: Q1 2021 earnings (% chge YoY)



Source: Refinitiv IBES data, Amundi Research, Data as of 14 May 2021

Defensives which had stood out early in the pandemic are last in line this year

Stoxx 600: a very robust rebound in Q1 results but so far due mainly to the receding in risks and to cost-cutting

Reporting season is also almost over in Europe, where 81% of Stoxx 600 companies had reported by 18 May. As in the United States, the rebound was surprisingly strong, at +93% in Q1, almost double what was being forecast at the start of reporting season (+47% on 1 April) and far ahead of forecasts being put out just three weeks ago (+71% on 27 April).

However, and unlike the US S&P 500, Stoxx 600 revenues were almost flat (+3% vs. +13%). As the starting point in this area in Q1 2020 is relatively near (-3% for the Stoxx 600 and -1% for the S&P), this is revealing of the widening gap between the two regions on both the macro (stimulus, lockdowns, vaccination, etc.) and microeconomic (sector weightings, pricing power, etc.) levels. Likewise, this suggests that the take-off in company results in Europe is, for the moment, due more to cost-cutting and lower risk provisions than to true leverage on sales.


By sector and generally speaking, defensives, which had stood out early in the pandemic, such as healthcare and utilities,

are last in line this year. Conversely, cyclical sectors, which had been hit the worst last year, are those that have rebounded the most this time, including consumer discretionary, energy, financials and industrials. Lastly, basic materials, which were driven initially by Chinese demand and, then gradually, by the reopening of other economies, are the only sector that has managed to fare better than average in both Q1 2020 and Q1 2021.


In light of base effects and the improvement in the health and economic environment, Stoxx 600 results should continue to improve and rebound strongly on a full-year basis, at +45%, according to the IBES consensus, including +93% in Q2, +32% in Q3 and +27% in Q4. Between the belated roll-out of vaccinations in Europe and the extension of lockdowns, the take-off expected for Q2 could be postponed in part to the second half of 2021 and early 2022. Be that as it may, although the acceleration of European economies is likely to be postponed by a few months, it is likely to happen eventually. That's why at this stage of the cycle, rather than growth stocks, defensives or large caps, it is worth overweighting value stocks, cyclicals and SMIDs.

THIS MONTH'S TOPIC

3/ Stoxx 600 quarterly results (YoY, %)



4/ Stoxx 600: Q1 2021 earnings (% chge YoY)



Emerging markets also fared very well

Reporting season is also well along in emerging markets. As of 14 May, 74% of MSCI EM companies had already reported their first quarter numbers (source: Capital IQ). Riding a favourable base effect – the Q1 2020 EPS having dropped by 34% with the almost total shutdown of economies early in the pandemic – and a very robust rebound in revenues early in the year (+21% in Q1 2021), emerging market earnings staged a true take-off, soaring by +87% in dollars (USD) and even more in local currencies weighted by the size of the various markets.

Of the 21 countries in our sample, Q1 2021 results fell in only two, Indonesia (-6%) and Argentina (-40%), while most others achieved not only double-digit, but triple-digit growth! Some 63% of emerging market companies have beaten the consensus, but the extent of the good surprises is also impressive, at +19% above initial forecasts. Just one country, India (-1%) has undershot forecasts, but its results were still up sharply (+62%). By sector, gains were, unsurprisingly, especially strong in

healthcare, basic materials and industry.

On a 12-month rolling basis, as of the end of March 2021, emerging markets results have moved back into positive territory (+4%), thanks mainly to the semiconductor-driven markets of Taiwan and Korea. Those regions still lagging behind on a 12-month rolling basis, such as Latin America and Russia within EMEA, are expected, in turn, to move back into positive territory in the coming quarters, while remaining volatile, due to base effects.

In reaction to these very good Q1 2021 numbers, we have raised our full-year EPS forecasts in emerging markets (in USD terms) from +24% at end-March to +34%.

In conclusion: beyond short-term doubts, a new phase in the market rally is looming – less strong but based more on fundamentals

Q1 2021 results rebounded to a surprising extent everywhere, with gains of about 50% in the US and 90% in Europe and in emerging markets, all of which benefited from a more favourable base effect. This bolsters consensus forecasts of a very

With 19 countries out of 21, emerging markets results bounced back on a wide front

THIS MONTH'S TOPIC

A new phase looks probable, in which earnings growth would play key role

strong rebound in full-year EPS, with +35% for the MSCI World AC. The rebound is likely to continue beyond 2021, with further growth of 12% in 2022 and 10% 2023.

So, after last year's rerating, a new phase looks probable, in which earnings growth would play a key role in market performance. In the shorter term, however, as many flags of a recovery, such as inflation expectations, ISM data and earnings net-up, are nearing their peaks, equity markets could become more tentative in the wake of their strong gains since March 2020.

But this is unlikely to cast any doubt on their favourable outlook nine to 12 months out, as phases of outperformance by cyclicals generally last more than two years. Although their second derivative reading

is receding, ISM and earnings forecasts are likely to remain very solid. Lastly, between rising interest rates and inflation, real rates are likely to remain quite moderate.

Amidst a likely generalised reopening of both developed and emerging economies, and in a context where bond yields should continue to move back to normal, it is probably worth sticking to a rather procyclical bias, in value stocks in particular, rather than defensives and growth stocks. However, as the recovery matures, stock-picking is expected to become more selective. In sort, relative value will take over from value, and alpha will take over from beta.

Finalised on 19 May 2021

Amundi Research Center



Find out more about
Amundi publications
research-center.amundi.com

Emerging Private Equity
Money Markets Find Monetary
Foreign Top-down Policies
Exchange Corporate Equities
Sovereign Bonds Forecasts
ESG Fixed Income Yield Real Estate
Quant Investment Asset
Strategies Allocation

DISCLAIMER

The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.mscibarra.com).

In the European Union, this document is only for the attention of "Professional" investors as defined in Directive 2004/39/EC dated 21 April 2004 on markets in financial instruments ("MIFID"), to investment services providers and any other professional of the financial industry, and as the case may be in each local regulations and, as far as the offering in Switzerland is concerned, a "Qualified Investor" within the meaning of the provisions of the Swiss Collective Investment Schemes Act of 23 June 2006 (CISA), the Swiss Collective Investment Schemes Ordinance of 22 November 2006 (CISO) and the FINMA's Circular 08/8 on Public Advertising under the Collective Investment Schemes legislation of 20 November 2008. In no event may this material be distributed in the European Union to non "Professional" investors as defined in the MIFID or in each local regulation, or in Switzerland to investors who do not comply with the definition of "qualified investors" as defined in the applicable legislation and regulation. This document is not intended for citizens or residents of the United States of America or to any "U.S. Person", as this term is defined in SEC Regulation S under the U.S. Securities Act of 1933. This document neither constitutes an offer to buy nor a solicitation to sell a product, and shall not be considered as an unlawful solicitation or an investment advice. Amundi accepts no liability whatsoever, whether direct or indirect, that may arise from the use of information contained in this material. Amundi can in no way be held responsible for any decision or investment made on the basis of information contained in this material. The information contained in this document is disclosed to you on a confidential basis and shall not be copied, reproduced, modified, translated or distributed without the prior written approval of Amundi, to any third person or entity in any country or jurisdiction which would subject Amundi or any of "the Funds", to any registration requirements within these jurisdictions or where it might be considered as unlawful. Accordingly, this material is for distribution solely in jurisdictions where permitted and to persons who may receive it without breaching applicable legal or regulatory requirements. The information contained in this document is deemed accurate as at the date of publication set out on the first page of this document. Data, opinions and estimates may be changed without notice.

You have the right to receive information about the personal information we hold on you. You can obtain a copy of the information we hold on you by sending an email to info@amundi.com. If you are concerned that any of the information we hold on you is incorrect, please contact us at info@amundi.com.

Document issued by Amundi Asset Management, "société par actions simplifiée" - SAS with a capital of €1,086,262,605 - Portfolio manager regulated by the AMF under number GP04000036 - Head office: 90 boulevard Pasteur - 75015 Paris - France - 437 574 452 RCS Paris - www.amundi.com
Photo credit: ©MDelporte - iStock/Getty Images Plus - PM Images

Chief editor

BLANQUÉ Pascal, *Group Chief Investment Officer*

Editor

DEFEND Monica, *Global Head of Research*

With Global Research contributors

AINOUZ Valentine, *Deputy Head of Developed Markets Strategy Research, CFA*
BELLACHE Mickael, *Fixed Income and Credit Research Strategist*
BERARDI Alessia, *Head of Emerging Macro and Strategy Research*
BERTONCINI Sergio, *Senior Fixed Income Research Strategist*
BLANCHET Pierre, *Head of Investment Intelligence*
BOROWSKI Didier, *Head of Global Views*
CESARINI Federico, *Cross Asset Research Strategist*
DELBO' Debora, *EM Macro Strategist*
DI SILVIO Silvia, *Macro Strategist*
DROZDZIK Patryk, *EM Macro Strategist*

With the Amundi Insights Unit contribution

BERTINO Claudia, *Head of Amundi Investment Insights Unit*
CARULLA POL, *Amundi Investment Insights Unit*

Conception & production

BERGER Pia, *Research*
PONCET Benoit, *Research*

Deputy-Editors

BLANCHET Pierre, *Head of Investment Intelligence*
BOROWSKI Didier, *Head of Global Views*

GEORGES Delphine, *Senior Fixed Income Research Strategist*
HERVÉ Karine, *EM Macro Strategist*
HUANG Claire, *EM Macro Strategist*
LEONARDI Michele, *Cross Asset Research Junior Analyst*
MIJOT Éric, *Head of Developed Markets Strategy Research*
PERRIER Tristan, *Global Views*
PORTELLI Lorenzo, *Head of Cross Asset Research*
STRENTA Aurelien, *Emerging Market Analyst (V.I.E)*
USARDI Annalisa, *Senior Economist Cross Asset Research*
VARTANESYAN Sasi, *Sovereign Analyst, Emerging Macro & Strategy Research*

FIOROT Laura, *Deputy Head of Amundi Investment Insights Unit*
DHINGRA Ujjwal, *Amundi Investment Insights Unit*
PANELLI Francesca, *Amundi Investment Insights Unit*